Status:
COMPLETED
Bioavailability Study of Cinnamon in Healthy Subjects
Lead Sponsor:
McCormick and Company, Inc.
Collaborating Sponsors:
Appalachian State University
Conditions:
Healthy Males
Eligibility:
MALE
18-40 years
Phase:
PHASE1
PHASE2
Brief Summary
A partial double-blind, randomized, placebo-controlled, 4-treatment crossover study design will be used to evaluate bioavailability of various forms of cinnamon and to determine the effects of 3 and 6...
Detailed Description
Objective: The objective of this trial is to evaluate the bioavailability of selected procyanidin derived metabolites from various forms of cinnamon. Study Products: Core Study * Control: Oatmeal ...
Eligibility Criteria
Inclusion
- Subject is a healthy male, 18 - 40 years of age, inclusive.
- Subject has a body mass index (BMI) 25.00-29.99 kg/m2
- Subject is willing to discontinue dietary supplement use for 2 weeks prior to the first test visit
- Subject is willing to avoid foods high in procyanidins for 2 d prior to the first test visit (visit 2, day 0) and throughout the trial.
- Subject does not smoke and has no plans to change smoking habits during the study period.
- Subject has a score of 7 to 10 on the Vein Access Scale at visit 1 (day -3;
- Subject is judged by the Investigator to be in general good health on the basis of physical examination and medical history.
- Subject understands the study procedures and signs forms providing informed consent to participate and authorization for release of relevant protected health information to the study Investigators.
Exclusion
- Subject has a history or presence of a gastrointestinal condition that could potentially interfere with absorption of the study product (e.g. inflammatory bowel syndrome, celiac disease, history of gastric bypass surgery).
- Subject has a history or presence of clinically important endocrine (including type 1 or 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, renal, hepatic, pancreatic, biliary or neurologic disorders that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
- Subject has a history or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- Subject has a current infection at visit 1 (day -3) or subject has an active infection or use of antibiotics within 5 d of any test visit (visits 2 through 5; days 0 through 21) and extension visit \[visit 6 (day 27); for the subset of subjects participating in the extension\]. For those with an active infection and/or using antibiotics, subjects must wait at least 5 d after the infection resolves or antibiotic use is complete to participate in a test visit.
- Subject has consumed alcoholic beverages within 24 h of any test day (visits 2 through 5; days 0 through 21) and the extension visit \[visit 6 (day 27); for the subset of subjects participating in the extension\].
- Subject has used any over-the-counter or prescription medications within 4 weeks of visit 1 (day -3)
- Subject has a history of any major trauma or major surgical event within 3 months of visit 1 (day -3).
- Subject has hypertension (systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg) at visit 1 (day -3).
- Subject has a history of allergy or sensitivity to any of the components of the study products, standard meal/snack or liquid meal.
- Subject has been exposed to any non-registered drug product within 30 d prior to visit 1 (day -3).
- Subject has a current or recent history (past 12 months of visit 1) or strong potential for drug or alcohol abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
- Individual has a condition the Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT01847053
Start Date
January 1 2013
End Date
April 1 2014
Last Update
March 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biofortis Clinical Research
Addison, Illinois, United States, 60101